Prostate cancer research identifies hormone therapy benefits and resistance mechanisms

Recent medical research has provided new insights into the treatment and resistance mechanisms of prostate cancer. A meta-analysis of six randomized Phase-3 studies examined the impact of adding hormone therapy to postoperative radiotherapy. The findings indicated that while the combination did not improve overall survival rates across the general group, patients with higher PSA levels prior to radiotherapy appeared to derive specific benefits.

In a separate development, researchers at the Fred Hutch Cancer Center published a study in the journal Nature regarding treatment resistance. The study identified that transfer RNA, specifically tRNA1Arg(UCU), acts as a molecular regulator in androgen receptor-dependent tumors. While this molecule is highly concentrated in sensitive cells, it is significantly reduced in therapy-resistant tumors. Experimental results demonstrated that restoring the levels of this specific tRNA could successfully make resistant tumor cells sensitive to androgen receptor inhibitors once again.